News

Filter

1 to 9 of 64 results

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

22-04-2014

Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and…

AlconBoardroomNorthern EuropeNovartisPharmaceuticalSandoz

French competition authority investigating Roche and Novartis over Lucentis marketing

10-04-2014

Following similar recent action by the equivalent Italian body, the French competition authority is launching…

AvastinBevacizumabFranceItalyLegalLucentisMarkets & MarketingMedicineNorthern EuropeNovartisOphthalmicsPharmaceuticalPharmacologyRocheUSD

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

1 to 9 of 64 results

COMPANY SPOTLIGHT

Menarini

Back to top